Терапевтический архив (Sep 2011)
Pandemic flu in Russia: special features of a clinical course and the absence of early etiotropic therapy as a risk factor of severe forms of the disease
- Lyudmila Vasil'evna Kolobukhina,
- L N Merkulova,
- M Yu Shchelkanov,
- E I Burtseva,
- V V Lavrishcheva,
- E I Samokhvalov,
- S V Al'khovskiy,
- A G Prilipov,
- E S Proshina,
- S N Avdeev,
- O A Sutochnikova,
- M V Bazarova,
- E I Kelli,
- N D Tserukalova,
- I A Blank,
- O M Shestakova,
- O N Kolivashko,
- T V Arseneva,
- O E Ambrosi,
- A A Shul'dyakov,
- A F Popov,
- A I Simakova,
- N A Malyshev,
- A G Chuchalin,
- D K L'vov,
- L V Kolobukhina,
- L N Merkulova,
- M Yu Schelkanov,
- E I Burtseva,
- V V Lavrischeva,
- E I Samokhvalov,
- S V Alkhovsky,
- A G Prilipov,
- E S Proshina,
- S N Avdeev,
- O A Sutochnikova,
- M V Bazarova,
- E I Kelli,
- N D Tserukalova,
- I A Blank,
- O M Shestakova,
- O N Kolivashko,
- T V Arseneva,
- O E Ambrosi,
- A A Shuldyakov,
- A F Popov,
- A I Simakova,
- N A Malyshev,
- A G Chuchalin,
- D K Lvov
Affiliations
- Lyudmila Vasil'evna Kolobukhina
- L N Merkulova
- M Yu Shchelkanov
- E I Burtseva
- V V Lavrishcheva
- E I Samokhvalov
- S V Al'khovskiy
- A G Prilipov
- E S Proshina
- S N Avdeev
- O A Sutochnikova
- M V Bazarova
- E I Kelli
- N D Tserukalova
- I A Blank
- O M Shestakova
- O N Kolivashko
- T V Arseneva
- O E Ambrosi
- A A Shul'dyakov
- A F Popov
- A I Simakova
- N A Malyshev
- A G Chuchalin
- D K L'vov
- L V Kolobukhina
- D.I. Ivanovsky Research Institute of Virology, Moscow
- L N Merkulova
- D.I. Ivanovsky Research Institute of Virology, Moscow
- M Yu Schelkanov
- D.I. Ivanovsky Research Institute of Virology, Moscow
- E I Burtseva
- D.I. Ivanovsky Research Institute of Virology, Moscow
- V V Lavrischeva
- D.I. Ivanovsky Research Institute of Virology, Moscow
- E I Samokhvalov
- D.I. Ivanovsky Research Institute of Virology, Moscow
- S V Alkhovsky
- D.I. Ivanovsky Research Institute of Virology, Moscow
- A G Prilipov
- D.I. Ivanovsky Research Institute of Virology, Moscow
- E S Proshina
- D.I. Ivanovsky Research Institute of Virology, Moscow
- S N Avdeev
- Research Institute of Pulmonology, Moscow
- O A Sutochnikova
- Research Institute of Pulmonology, Moscow
- M V Bazarova
- Infectious hospital N 1, Moscow
- E I Kelli
- Infectious hospital N 1, Moscow
- N D Tserukalova
- Infectious hospital N 1, Moscow
- I A Blank
- Infectious hospital N 1, Moscow
- O M Shestakova
- Infectious hospital N 1, Moscow
- O N Kolivashko
- Infectious hospital N 1, Moscow
- T V Arseneva
- Infectious hospital N 1, Moscow
- O E Ambrosi
- Infectious hospital N 1, Moscow
- A A Shuldyakov
- V.I. Razumovsky State Medical University, Saratov
- A F Popov
- State Medical University, Vladivostok
- A I Simakova
- State Medical University, Vladivostok
- N A Malyshev
- Infectious hospital N 1, Moscow
- A G Chuchalin
- Research Institute of Pulmonology, Moscow
- D K Lvov
- D.I. Ivanovsky Research Institute of Virology, Moscow
- Journal volume & issue
-
Vol. 83,
no. 9
pp. 48 – 53
Abstract
Aim. To assess efficacy and safety of ingavirin in the treatment of the flu caused by pandemic virus of flu A (H1N1) sw1 in hospitalized patients compared with oseltamivir. Material and methods. A population-based comparative multicenter trial included 194 patients with verified diagnosis of the flu aged 18-60 years with marked clinical symptoms, body temperature over 38 °C and duration of the disease 48 hours maximum. The patients were randomized into 2 groups: group 1 (n = 152) received ingavirin (90 mg once a day), group 2 received oseltamivir (n = 42) in a dose 150 mg twice a day. Duration of the course was 5 days. Results. Ingavirin and oseltamivir normalized body temperature within treatment hours 24-36 if therapy was initiated in the first disease hours 27.0±10.0 and 31.9±10.4. Mean duration of the fever for ingavirin was 35.1±14.5 hours, for oseltamivir - 26.3±13.0 hours (p < 0.817). The antiviral medicines significantly reduced duration of intoxication (head ache, weakness), catarrhal symptoms (cough, tracheitis, rhinitis), rate of complication vs patients untreated with antivirus drugs (n = 30). Conclusion. The results of the treatment show safety and efficacy of ingavirin in uncomplicated flu caused by pandemic virus of flu A (H1N1) sw1 in inpatients. Early etiotropic therapy is a basic treatment policy able to reduce the number of severe complications and lethality.
